Confronto
Buserelin vs. Gonadorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
57982-77-1
33515-09-2
Peso molecolare
1239.42 g/mol
1182.29 g/mol
Emivita
nessun dato
0.1 h
Sequenza
nessun dato
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2Meccanismo d'azione
Buserelin
Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
0
4
di cui sull'uomo
0
4
Effetti registrati
2
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Buserelin and Gonadorelin?
- Buserelin is classified as "Ricerca (altro)", while Gonadorelin is classified as "Ricerca (altro)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Buserelin or Gonadorelin?
- The highest available evidence level is "RCT sull'uomo" for Buserelin and "Studio sull'uomo" for Gonadorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Buserelin and Gonadorelin in Germany and the United States?
- Germania: Buserelin — Su prescrizione, Gonadorelin — Su prescrizione. Stati Uniti: Buserelin — Non approvato, Gonadorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.